The stock of Alnylam Pharmaceuticals Inc (ALNY) has seen a -1.84% decrease in the past week, with a 6.47% gain in the past month, and a 7.37% flourish in the past quarter. The volatility ratio for the week is 2.65%, and the volatility levels for the past 30 days are at 2.51% for ALNY. The simple moving average for the past 20 days is 0.71% for ALNY’s stock, with a 37.45% simple moving average for the past 200 days.
Is It Worth Investing in Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) Right Now?
Company’s 36-month beta value is 0.38.Analysts have differing opinions on the stock, with 11 analysts rating it as a “buy,” 2 as “overweight,” 4 as “hold,” and 1 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALNY is 127.24M, and currently, short sellers hold a 3.50% ratio of that floaft. The average trading volume of ALNY on October 04, 2024 was 853.89K shares.
ALNY) stock’s latest price update
The stock price of Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has dropped by -0.74 compared to previous close of 271.55. Despite this, the company has seen a fall of -1.84% in its stock price over the last five trading days. zacks.com reported 2024-10-02 that Alnylam’s Amvuttra and Givlaari sales continue to boost revenues. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.
Analysts’ Opinion of ALNY
Many brokerage firms have already submitted their reports for ALNY stocks, with Goldman repeating the rating for ALNY by listing it as a “Buy.” The predicted price for ALNY in the upcoming period, according to Goldman is $370 based on the research report published on August 16, 2024 of the current year 2024.
Goldman, on the other hand, stated in their research note that they expect to see ALNY reach a price target of $173. The rating they have provided for ALNY stocks is “Neutral” according to the report published on February 16th, 2024.
ALNY Trading at 1.78% from the 50-Day Moving Average
After a stumble in the market that brought ALNY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.27% of loss for the given period.
Volatility was left at 2.51%, however, over the last 30 days, the volatility rate increased by 2.65%, as shares surge +7.18% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +13.98% upper at present.
During the last 5 trading sessions, ALNY fell by -1.84%, which changed the moving average for the period of 200-days by +45.50% in comparison to the 20-day moving average, which settled at $268.52. In addition, Alnylam Pharmaceuticals Inc saw 40.81% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALNY starting from Greenstreet Yvonne, who sale 15,000 shares at the price of $280.00 back on Aug 20 ’24. After this action, Greenstreet Yvonne now owns 73,441 shares of Alnylam Pharmaceuticals Inc, valued at $4,200,000 using the latest closing price.
Greenstreet Yvonne, the Officer of Alnylam Pharmaceuticals Inc, proposed sale 15,000 shares at $280.00 during a trade that took place back on Aug 20 ’24, which means that Greenstreet Yvonne is holding shares at $4,200,000 based on the most recent closing price.
Stock Fundamentals for ALNY
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.87 for the gross margin
The net margin for Alnylam Pharmaceuticals Inc stands at -0.03. The total capital return value is set at 0.03.
Based on Alnylam Pharmaceuticals Inc (ALNY), the company’s capital structure generated 1.0 points at debt to capital in total, while cash flow to debt ratio is standing at 0.15. The debt to equity ratio resting at -804.98. The interest coverage ratio of the stock is 0.79.
Currently, EBITDA for the company is -228.12 million with net debt to EBITDA at 15.48. When we switch over and look at the enterprise to sales, we see a ratio of 15.5. The receivables turnover for the company is 7.58for trailing twelve months and the total asset turnover is 0.58. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.01.
Conclusion
In a nutshell, Alnylam Pharmaceuticals Inc (ALNY) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
